FR3063640B1 - TREATMENT OF PULMONARY FIBROSIS USING A SELECTIVE INHIBITOR OF THE PRODUCTION OF REACTIVE OXYGEN SPECIES OF MITOCHONDRIAL ORIGIN - Google Patents

TREATMENT OF PULMONARY FIBROSIS USING A SELECTIVE INHIBITOR OF THE PRODUCTION OF REACTIVE OXYGEN SPECIES OF MITOCHONDRIAL ORIGIN Download PDF

Info

Publication number
FR3063640B1
FR3063640B1 FR1751836A FR1751836A FR3063640B1 FR 3063640 B1 FR3063640 B1 FR 3063640B1 FR 1751836 A FR1751836 A FR 1751836A FR 1751836 A FR1751836 A FR 1751836A FR 3063640 B1 FR3063640 B1 FR 3063640B1
Authority
FR
France
Prior art keywords
treatment
pulmonary fibrosis
oxygen species
reactive oxygen
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1751836A
Other languages
French (fr)
Other versions
FR3063640A1 (en
Inventor
Olivier Petitjean
Guillaume Petitjean
Elodie Petitjean
Gregoire Petitjean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childs Marc
Original Assignee
Childs Marc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childs Marc filed Critical Childs Marc
Priority to FR1751836A priority Critical patent/FR3063640B1/en
Priority to CA3054992A priority patent/CA3054992A1/en
Priority to PCT/FR2018/050521 priority patent/WO2018162845A1/en
Priority to JP2019548367A priority patent/JP2020510675A/en
Priority to US16/492,546 priority patent/US11554106B2/en
Priority to EP18712965.5A priority patent/EP3592427A1/en
Publication of FR3063640A1 publication Critical patent/FR3063640A1/en
Application granted granted Critical
Publication of FR3063640B1 publication Critical patent/FR3063640B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a trait à la prévention et /ou au traitement des maladies dans lesquelles sont impliquées les espèces réactives de l'oxygène (ou ROS) d'origine mitochondriale. Elle concerne plus particulièrement l'utilisation d'un inhibiteur spécifique de la production de ROS mitochondriale, en particulier l'anethole trithione, pour le traitement et la prévention de la fibrose pulmonaire.The present invention relates to the prevention and / or treatment of diseases in which reactive oxygen species (or ROS) of mitochondrial origin are involved. It relates more particularly to the use of a specific inhibitor of mitochondrial ROS production, in particular anethole trithione, for the treatment and prevention of pulmonary fibrosis.

FR1751836A 2017-03-07 2017-03-07 TREATMENT OF PULMONARY FIBROSIS USING A SELECTIVE INHIBITOR OF THE PRODUCTION OF REACTIVE OXYGEN SPECIES OF MITOCHONDRIAL ORIGIN Active FR3063640B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1751836A FR3063640B1 (en) 2017-03-07 2017-03-07 TREATMENT OF PULMONARY FIBROSIS USING A SELECTIVE INHIBITOR OF THE PRODUCTION OF REACTIVE OXYGEN SPECIES OF MITOCHONDRIAL ORIGIN
CA3054992A CA3054992A1 (en) 2017-03-07 2018-03-07 Prevention of the risks associated with drug-induced qt interval prolongation by using a specific inhibitor of the production of ros of mitochondrial origin
PCT/FR2018/050521 WO2018162845A1 (en) 2017-03-07 2018-03-07 Prevention of the risks associated with drug-induced qt interval prolongation by using a specific inhibitor of the production of ros of mitochondrial origin
JP2019548367A JP2020510675A (en) 2017-03-07 2018-03-07 Prevention of risks associated with drug-induced QT interval prolongation using specific inhibitors of the production of ROS of mitochondrial origin
US16/492,546 US11554106B2 (en) 2017-03-07 2018-03-07 Prevention of the risks associated with drug-induced QT interval prolongation by using a specific inhibitor of the production of ROS of miochondrial origin
EP18712965.5A EP3592427A1 (en) 2017-03-07 2018-03-07 Prevention of the risks associated with drug-induced qt interval prolongation by using a specific inhibitor of the production of ros of mitochondrial origin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1751836A FR3063640B1 (en) 2017-03-07 2017-03-07 TREATMENT OF PULMONARY FIBROSIS USING A SELECTIVE INHIBITOR OF THE PRODUCTION OF REACTIVE OXYGEN SPECIES OF MITOCHONDRIAL ORIGIN
FR1751836 2017-03-07

Publications (2)

Publication Number Publication Date
FR3063640A1 FR3063640A1 (en) 2018-09-14
FR3063640B1 true FR3063640B1 (en) 2020-10-09

Family

ID=59409406

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1751836A Active FR3063640B1 (en) 2017-03-07 2017-03-07 TREATMENT OF PULMONARY FIBROSIS USING A SELECTIVE INHIBITOR OF THE PRODUCTION OF REACTIVE OXYGEN SPECIES OF MITOCHONDRIAL ORIGIN

Country Status (1)

Country Link
FR (1) FR3063640B1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
TW200640898A (en) * 2005-02-24 2006-12-01 Solvay Pharm Bv Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
EP3148528A1 (en) * 2014-06-02 2017-04-05 University of Exeter Combinations of a photosensitizer with a hydrogen sulfide donor, thioredoxin inhibitor or nitroxide for use in photodynamic therapy
AU2016319184B2 (en) * 2015-09-08 2022-03-31 Centre Hospitalier Universitaire De Bordeaux Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production

Also Published As

Publication number Publication date
FR3063640A1 (en) 2018-09-14

Similar Documents

Publication Publication Date Title
WO2002076939A3 (en) Cysteine protease inhibitors
MA53816A (en) FUSED PYRROLINES THAT ACT AS UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) INHIBITORS
TR200002940T2 (en) Treatment of diseases caused by parasites by inhibition of cysteine proteases from the papain superfamily
NO20061627L (en) Haloalkyl containing compounds as cysteine protease inhibitors
MA29976B1 (en) USE OF COMPLEMENTARY INHIBITORS FOR TREATING OCULAR DISEASES.
FR3060324B1 (en) COMPOSITION COMPRISING AT LEAST TWO ANIONIC SURFACTANTS, NON-IONIC SURFACTANT AND AMPHOTERIC SURFACTANT, AND AT LEAST ONE ANTI-DELL AGENT
MX2018002962A (en) Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production.
MA46548A (en) FSH FOR INFERTILITY TREATMENT
PE20210553A1 (en) VARIANTS AND ISOFORMS OF ANTIBODIES WITH REDUCED BIOLOGICAL ACTIVITY
ATE487384T1 (en) DEVICE AND METHOD FOR CLEANING THE ABDOMINAL CAVITY OF FISH
FR3063640B1 (en) TREATMENT OF PULMONARY FIBROSIS USING A SELECTIVE INHIBITOR OF THE PRODUCTION OF REACTIVE OXYGEN SPECIES OF MITOCHONDRIAL ORIGIN
FR3044923B1 (en) COSMETIC AGENTS THAT CONTAIN AT LEAST THREE DIFFERENT PRESERVATIVES
IL307926A (en) Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
PH12019500075A1 (en) Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
FR3075038B1 (en) USE OF FLUOROETHYLNORMEMANTINE FOR THE PREVENTION OF THE APPEARANCE AND THE TREATMENT OF ANXIETY
MA31631B1 (en) Polygalacteronase is new and its uses
FR3092998B1 (en) Cosmetic composition based on plant products
FR3116723B1 (en) Powdered cosmetic cleaning agent
MA45855B1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
FR3079145B1 (en) USE OF DRY FILM FOR TOPICAL COSMETIC APPLICATIONS
MX2021013634A (en) Stable albuvirtide compositions.
MA53200B1 (en) One piece shower head
AR108150A1 (en) COMPOSITION FOR ORAL CARE
FR3127878B1 (en) hair treatment compositions providing luminosity and shine
FR3106978B1 (en) USE OF A MOLECULE INHIBITING THE PRODUCTION OF ROS OF MITOCHONDRIAL ORIGIN SUCH AS ANETHOLE TRITHIONE TO TREAT PARKINSON'S DISEASE

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180914

PLFP Fee payment

Year of fee payment: 3

CL Concession to grant licences

Name of requester: ZION PHARMA, FR

Effective date: 20190916

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7